Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback